Key facts
- Neurolief’s last known valuation is $36.4M (Mar 2026).
- It has raised $23.4M; the latest was Later Stage VC ($11.0M) in Mar 2026.
- Notable investors include Brainsway, Champel Capital, KT Squared, Sawai Group Holdings, Terra Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Neurolief
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurolief are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurolief
Developer of a brain neuromodulation device designed to treat neurological and neuropsychiatric disorders. The company develops a non-invasive device integrated with a digital therapeutics platform, enabling patients to receive treatment for migraine and depression without invasive procedures or medication-related side effects.
- Sector
- Healthcare
- HQ
- Netanya, Israel
- Founded
- 2013
- Employees
- 28
- Website
- neurolief.com/
- Ownership
- Privately Held (backing)
Neurolief doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurolief shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurolief in its N-PORT filings yet. We sweep new filings monthly.